GlassScriptPhysician profile
Sarbabi Masindet
NPI 1457464471
$4,006.45
in general payments reported to CMS, 2019-2025
28 companies · $558 in 2025
The $558 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $745 · 2020: $403 · 2021: $501 · 2022: $785 · 2023: $616 · 2024: $399 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,572.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $610.57 | 2019-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $423.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $393.62 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $341.82 | 2019-2025 | Camzyos |
| Biotronik INC. | $308.68 | 2020-2025 | Amvia Edge |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.35 | 2019-2022 | |
| Amgen INC. | $246.64 | 2019-2025 | Repatha, Repatha |
| Scpharmaceuticals INC. | $215.00 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $204.59 | 2021-2025 | Onpattro, Amvuttra |
| Vital Connect, INC | $184.66 | 2022-2023 | Vitalpatch Rtm |
| Pfizer INC. | $139.12 | 2019-2023 | |
| Abbott Laboratories | $114.04 | 2022-2023 | Gallant |
| Janssen Pharmaceuticals, INC | $77.87 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $56.61 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $55.10 | 2024 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $46.27 | 2025 | Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $40.18 | 2019 | |
| Akcea Therapeutics, INC. | $33.96 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $32.60 | 2023-2024 | Inpefa |
| Baxter Healthcare | $30.87 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $28.85 | 2024 | Optimizer |
| Medtronic, INC. | $28.52 | 2024 | Tyrx |
| Bayer Healthcare Pharmaceuticals INC. | $27.17 | 2025 | |
| Heartflow, INC. | $24.87 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $24.79 | 2023 | Arcalyst |
| Cardinal Health 200 LLC | $15.97 | 2019 | |
| Edwards Lifesciences Corporation | $13.03 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| G Medical Diagnostic Services, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarbabi Masindet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.